This page shows circumstances of Amgen's Repatha (evolocumab, anti-PCSK9 antibody)-related patents in Japan.
Table of contents
(a) Relation of six Repatha-related patents and Re-examination period (data exclusivity period)
(b) Claims of six Repatha-related patents
(c) Lawsuits of Repatha-related patents
PDF view
PDF view
PDF view
PDF view
PDF view
PDF view
The court decisions are described on the court web page (PDF file) below.
1) Revocation suit against JPO trial decision (Case No.: 2017 (Gyo-Ke) 10225)
Decided: December 27, 2018, Intellectual Property High Court (English translation)
http://www.ip.courts.go.jp/app/files/hanrei_en/456/002456.pdf
2) Revocation suit against JPO trial decision (Case No.: 2017 (Gyo-Ke) 10226)
Decided: December 27, 2018, Intellectual Property High Court (English translation)
http://www.ip.courts.go.jp/app/files/hanrei_en/417/002417.pdf
3) Infringement lawsuit (Amgen v. Sanofi) (Case No.: 2017 (Gyo-Wa) 16468)
Decided: October 9, 2018, Tokyo District Court (Japanese)
http://www.courts.go.jp/app/files/hanrei_jp/330/088330_hanrei.pdf
